Pular para o conteúdo
Merck
  • Hypoxia induces miR-153 through the IRE1α-XBP1 pathway to fine tune the HIF1α/VEGFA axis in breast cancer angiogenesis.

Hypoxia induces miR-153 through the IRE1α-XBP1 pathway to fine tune the HIF1α/VEGFA axis in breast cancer angiogenesis.

Oncogene (2018-01-26)
Huichun Liang, Ji Xiao, Zhongmei Zhou, Jiao Wu, Fei Ge, Zongcheng Li, Hailin Zhang, Jian Sun, Fubing Li, Rong Liu, Ceshi Chen
RESUMO

It is well documented that hypoxia activates the hypoxia-inducible factor 1-alpha (HIF1α)/vascular endothelial growth factor A (VEGFA) axis to promote angiogenesis in breast cancer. However, it is unclear how this axis is negatively regulated. In this study, we demonstrated that miR-153 directly inhibits expression of HIF1α by binding to the 3'UTR of HIF1A mRNA, as well as suppresses tube formation of primary human umbilical vein endothelial cells (HUVECs) and breast cancer angiogenesis by decreasing the secretion of VEGFA. Importantly, expression of miR-153 was induced by hypoxia-stimulated ER stress, which activates IRE1α and its downstream transcription factor X-box binding protein 1 (XBP1). X-box binding protein 1 directly binds to the promoter of the miR-153 host gene PTPRN and activates transcription. These results indicate that hypoxia induces miR-153 to fine tune the HIF1α/VEGFA axis in breast cancer angiogenesis and miR-153 could be used for breast cancer anti-angiogenesis therapy.

MATERIAIS
Número do produto
Marca
Descrição do produto

Sigma-Aldrich
Antiβ-actina monoclonal, clone AC-15, ascites fluid
Sigma-Aldrich
Anti-PTPRN antibody produced in rabbit, affinity isolated antibody